Human VEGF Receptor 2 Antibody Pair - BSA and Azide free (RMAB-0252174)
Cat. No.: RMAB-0252174
Category: Antibody Pair
INQUIRY
10 x 96 tests
The Antibody Pair can be used to quantify Human VEGF Receptor 2. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/mL as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results._x000D_
Product Features
| Conjugate | Unconjugated capture and detector antibodies |
|---|---|
| Species Reactivity | Human |
| Range | 62.5 pg/mL - 4000 pg/mL |
| Applications | Sandwich ELISA |
| Key Features | Unconjugated capture and detector antibodies; Adaptable to any antibody pair-based assay format; Antibody concentration ~ 1 mg/mL; BSA and azide free buffer - ready for conjugation; Reacts with: Human |
Target Information
| Target Symbol | KDR |
|---|---|
| Target Name | Vascular endothelial growth factor receptor 2 |
| UniProt ID | P35968 |
| Cellular Localization | Membrane. |
| Function | Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. |
| Involvement in Disease | Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI). HCI are benign, highly proliferative lesions involving localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of% per year and replacement by fibrofatty stroma. |
| Post-translational Modifications | Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. |
| Sequence Similarities | Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. Contains 7 Ig-like C2-type (immunoglobulin-like) domains. Contains 1 protein kinase domain. |
Storage & Shipping
| Storage & Shipping | Store at 4°C. Please refer to protocols. |
|---|
For research use only. Not for clinical use.
